Protective Immunity to Human Cholera in Bangladesh
Mo kle
Abstrè
Deskripsyon
Diarrheal diseases are some of the most common causes of morbidity and mortality in the world today. Unfortunately, effective vaccines for most of the infectious causes of diarrhea are not yet available. Vibrio cholerae (V cholerae) is an important infectious cause of severe secretory diarrhea in humans. The purpose of this study is to assess the duration of immune responses in a group of 250 individuals, aged 2-60 years, presenting to the International Centre for Diarrheal Diseases Research, Bangladesh (ICDDR,B) hospital who are admitted with acute cholera. Fifty of these participants will be enrolled in a substudy of mucosal immunity involving duodenal biopsy. This protocol focuses exclusively on the subset of 50 study participants (healthy 18-45 year old non pregnant subjects) enrolled in the substudy of mucosal immunity involving duodenal biopsy. This study is linked to DMID protocol 06-0045. The remainder of the study is observational, involving collection of stool, vomit, and blood samples only (DMID protocol 06-0045). A duodenal biopsy will be performed on enrollment or the next day and at Day 30. Twenty five subjects will undergo a third duodenal biopsy after 6 months of follow-up and 25 subjects will undergo a third duodenal biopsy after 12 months follow-up. The objectives of this study are as follows: to measure immune responses directed against Vibrio cholerae antigens and evaluate the development of anti-V cholerae memory B cells in study participants with cholera; to assess the duration of the immune responses following an episode of cholera; and to correlate the duration of antigen-specific, antibody-secreting cells for various cholera antigens in duodenal tissue with measurements of the duration of immunity based on antibody responses in serum, as well as circulating antigen-specific memory B cells. This is a single site study with a 5 year duration requiring three years of patient participation.
Dat
| Dènye verifye: | 09/30/2009 |
| Premye Soumèt: | 07/05/2006 |
| Enskripsyon Estimasyon Soumèt: | 07/05/2006 |
| Premye afiche: | 07/09/2006 |
| Dènye Mizajou Soumèt: | 09/04/2013 |
| Dènye Mizajou afiche: | 09/08/2013 |
| Dat aktyèl kòmanse etid la: | 05/31/2008 |
| Dat Estimasyon Prensipal Estimasyon an: | 12/31/2011 |
| Dat estime fini etid la: | 11/30/2012 |
Kondisyon oswa maladi
Faz
Gwoup bra
| Bra | Entèvansyon / tretman |
|---|---|
| 1 18 males and non pregnant females, ages 18-45, with acute cholera. |
Kritè kalifikasyon yo
| Laj ki kalifye pou etid | 18 Years Pou 18 Years |
| Sèks ki kalifye pou etid | All |
| Metòd echantiyonaj | Non-Probability Sample |
| Aksepte Volontè Healthy | Wi |
| Kritè | Inclusion Criteria: For the esophagogastroduodenoscopy (EGD) substudy of 50 study participants - Admission to the International Centre for Diarrhoeal Diseases Research, Bangladesh (ICDDR,B) with acute cholera - Male or nonpregnant female [pregnancy will be excluded by urine human chorionic gonadotropin (HCG) testing] - Age 18 to 45 years, inclusive - Residence in Dhaka city - Provision of informed consent for enrollment in study - Expressed interest and availability to fulfill the study requirements Exclusion Criteria: For the esophagogastroduodenoscopy (EGD) substudy of 50 study participants - Participation in any other investigational drug, device or vaccine trial at present or within the past 30 days - Known allergy to midazolam or topical anesthetics - Presence of comorbid conditions, including: - heart disease - pulmonary disease - liver disease - kidney disease - bleeding disorder - neurologic disorder - an additional intestinal disorder - pregnancy - anemia (hemoglobin < 12 g/dl for males or < 11 g/dl for female) - hypotension (systolic blood pressure less than or equal to 85 mm Hg or diastolic blood pressure less than or equal to 55 mm Hg, measured in the supine position once just prior to procedure) - hypertension (systolic blood pressure greater than or equal to 150 mm Hg or diastolic blood pressure greater than or equal to 90 mm Hg, measured in the supine position once just prior to procedure) |
Rezilta
Mezi Rezilta Prensipal yo
1. Serum antibody responses to V cholerae Lipopolysaccharide (LPS) and Cholera Toxin, B Subunit (CTB) (and other antigens as needed) on Days 2, 7, and 30 and at Months 3, 6, 9, 12, 18, 24, 30, and 36 following enrollment. [Days 2, 7, and 30 and at Months 3, 6, 9, 12, 18, 24, 30, and 36 following enrollment.]
2. Mucosal responses to V cholerae LPS and CTB (and other antigens as needed) on Days 2 and 30 (in 50 study participants) and at Month 6 (25 study participants) and Month 12 (25 study participants) following enrollment. [Days 2 and 30 (in 50 participants) and at Month 6 (25 study participants) and Month 12 (25 study participants) following enrollment.]
3. Memory B and T cell responses to V cholerae LPS and CTB (and other antigens as needed) on Days 2 and 30 and at Months 3, 6, 9, 12, 18, 24, 39, and 36 following enrollment. [Days 2 and 30 and at Months 3, 6, 9, 12, 18, 24, 39, and 36 following enrollment..]
